Singapore markets closed

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.04-0.07 (-0.32%)
At close: 04:00PM EST
22.04 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close22.11
Bid21.25 x 1300
Ask24.50 x 1200
Day's range21.84 - 22.31
52-week range18.02 - 33.00
Avg. volume1,273,798
Market cap3.564B
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)-0.57
Earnings date09 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.78
  • Zacks

    Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe

    Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

  • Zacks

    Down 21.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Alkermes (ALKS)

    Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • Motley Fool

    Why Alkermes Stock Is Sinking Today

    Shares of Alkermes (NASDAQ: ALKS) were sinking 14.3% as of 11 a.m. EST on Tuesday. The decline came after the company announced on Monday that it had received notices of partial termination from Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary related to license agreements for Alkermes' NanoCrystal technology. Partial termination of the two license agreements affects royalties that Alkermes receives from J&J for antipsychotic drugs Invega Sustenna and Invega Trinza.